Metabolic

Petrelintide

Also called ZP8396

InjectableEvidence BOnce a week

Half-life

168hours

Typical vial

5 / 10mg

Research amounts

0.3–2.4mg

per administration

Common schedule

Once a week

Some human use

It has been used in people, but no trial has settled how much or how often.

Work out your draw

These numbers are a starting point — change any of them.

Amount in the vialmgBacteriostatic water you addmLAmount per drawmgAmount unitDevice

Concentration: 1.67mg/mL
Volume per draw: 0.18mL
Units to dial: 18
Doses per cartridge: 16

Vial label

Copy this into your label printer.

Label nameDate you mixed itFormatFor 24 mm tape, or 1" x 2 1/8" die-cut stock such as Dymo 30336.

Petrelintide  1.67 mg/mL
18 units = 0.3 mg
Recon 2026-09-17

Published research contexts for Petrelintide describe 0.3–2.4 mg per administration. Descriptive only, not a recommendation.

A long-acting amylin analog dosed weekly; published human pharmacokinetics are thin.

A long-acting amylin analog studied for weight reduction in phase 1/2 research. No confirmed dose-ranging publication fixes a subcutaneous schedule, so no schedule table is shown.

Modelled level — once a week

1× is the peak after a single dose.

Steady-state peak: 1.98× single dose
Time to steady state: 35.0days
Administrations: 1/ week

Where these numbers come from

Petrelintide (ZP8396) early-phase program (Zealand Pharma)Weekly subcutaneous amylin-analog dosing in early-phase weight research; no dose-ranging trial has fixed a schedule.

Next steps

Plan Petrelintide alongside other compounds Work out cost per draw